Ackrell Capital, LLC
OrganizationRelationship Network
| Connected Entity | Relationship Type |
Strength
(mentions)
|
Documents | Actions |
|---|---|---|---|---|
|
person
FINRA / SIPC
|
Membership |
7
|
3 | |
|
organization
FINRA
|
Membership |
6
|
2 | |
|
organization
SIPC
|
Membership |
6
|
2 | |
|
organization
Wana Brands
|
Investment analysis |
5
|
1 | |
|
person
FINRA/SIPC
|
Membership |
5
|
1 | |
|
organization
VCC Brands
|
Investment analysis |
5
|
1 | |
|
organization
Uber
|
Investment analysis |
5
|
1 | |
|
organization
Vapexhale
|
Investment analysis |
5
|
1 | |
|
organization
SC Labs
|
Business associate |
1
|
1 |
HOUSE_OVERSIGHT_024725.jpg
This document is page 89 of a 2017 report by Ackrell Capital regarding the U.S. legal landscape for cannabis. It predicts legislative changes in 2018 for various states and analyzes the timeline for federal legalization based on public support data from Gallup. The document bears a 'HOUSE_OVERSIGHT_024725' Bates stamp, indicating it was part of a document production to the House Oversight Committee, though the content itself is a general market analysis rather than specific correspondence.
HOUSE_OVERSIGHT_024724.jpg
This page from an Ackrell Capital investment report outlines three potential regulatory scenarios for the future of cannabis in the United States. It details hypothetical frameworks for the FDA routine approval of CBD and THC drugs, as well as a broader scenario where the federal government fully legalizes cannabis and establishes a new regulatory agency.
HOUSE_OVERSIGHT_024722.jpg
This document is page 86 of a December 2017 Cannabis Investment Report by Ackrell Capital. It discusses the regulatory landscape involving the DEA and FDA, specifically highlighting GW Pharmaceuticals' NDA for Epidiolex and providing six predictions regarding the path to federal cannabis legalization in the US. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was likely part of a document production for a congressional investigation.
HOUSE_OVERSIGHT_024721.jpg
This document is page 85 of a 2017 report by Ackrell Capital regarding the U.S. legal landscape for cannabis. It discusses the path to federal legalization, analyzing the roles of the DEA and FDA, the conflict between state and federal regulations, and the bureaucratic hurdles stalling the approval of cannabis-derived drugs under the leadership of Attorney General Jeff Sessions. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was part of a document production for a congressional oversight committee.
HOUSE_OVERSIGHT_024720.jpg
This document is page 84 of a 'Cannabis Investment Report' dated December 2017, published by Ackrell Capital, LLC. The text details the legal complexities of intellectual property protection for cannabis businesses, specifically discussing the USDA's Plant Variety Protection Act (PVPA) and the federal Trademark Act (Lanham Act). It highlights that federal trademark registration is generally unavailable for products that are illegal under federal law, though some ancillary products (like clothing) may be eligible. The page bears a 'HOUSE_OVERSIGHT_024720' stamp, indicating it was part of document production for a House Oversight Committee investigation.
HOUSE_OVERSIGHT_024719.jpg
This document is page 83 of a 2017 report by Ackrell Capital regarding the U.S. legal landscape for cannabis. It details the application of Section 280E of the tax code to cannabis businesses and discusses the Patent Act, listing several specific cannabis-related patents issued by the USPTO (including one held by the U.S. federal government) despite the drug's federal illegality. The document bears a House Oversight Committee Bates stamp, but contains no direct text references to Jeffrey Epstein or his associates on this specific page.
HOUSE_OVERSIGHT_024717.jpg
This document is page 81 of a 2017 report by Ackrell Capital titled 'U.S. Legal Landscape' (Chapter IV). It analyzes federal securities laws and bankruptcy laws specifically in the context of the cannabis industry, noting that while securities laws allow capital raising, bankruptcy protection is generally unavailable due to federal illegality. It cites the 2015 Arizona case 'In Re Medpoint Management, LLC' as a precedent for denying bankruptcy protection based on the 'unclean hands' doctrine.
HOUSE_OVERSIGHT_024716.jpg
This document is page 80 of a December 2017 Cannabis Investment Report by Ackrell Capital. It summarizes the findings of the California State Treasurer's Cannabis Banking Working Group regarding the banking difficulties faced by the cannabis industry and outlines recommendations for state and federal action. The lower half of the page provides a general overview of Federal Securities Law (1933 and 1934 Acts) and the role of the SEC. The document bears a House Oversight Committee Bates stamp, suggesting it was part of a larger document production, likely related to financial investigations.
HOUSE_OVERSIGHT_024715.jpg
This document is page 79 of a report by Ackrell Capital, titled 'Chapter IV U.S. Legal Landscape'. It presents data sourced from the Financial Crimes Enforcement Network regarding 'Marijuana-Related SAR Filings' between Q2 2014 and Q2 2017. The page argues that the increasing trend in these filings indicates cannabis businesses are accessing the federal banking system despite federal prohibitions. The document bears a 'HOUSE_OVERSIGHT_024715' Bates stamp.
HOUSE_OVERSIGHT_024714.jpg
This page from an Ackrell Capital Cannabis Investment Report outlines seven due diligence steps for financial institutions dealing with marijuana-related businesses. It also details the FinCEN Memo's guidelines for filing Suspicious Activity Reports (SARs), specifically distinguishing between "Marijuana Limited," "Marijuana Priority," and "Marijuana Termination" filings.
HOUSE_OVERSIGHT_024713.jpg
This document is page 77 of a 2017 report by Ackrell Capital, LLC, discussing the U.S. legal landscape for the cannabis industry. It specifically details the Bank Secrecy Act (BSA), money laundering statutes, and the 2014 FinCEN Memo regarding how financial institutions should handle marijuana-related businesses and file Suspicious Activity Reports (SARs). The document bears a 'HOUSE_OVERSIGHT' Bates stamp, suggesting it was part of a document production for a congressional investigation, though the text itself does not mention Jeffrey Epstein.
HOUSE_OVERSIGHT_024712.jpg
Page 76 of a December 2017 Cannabis Investment Report authored by Ackrell Capital. The text analyzes the regulatory landscape for cannabis-based foods and dietary supplements under the FD&C Act, specifically focusing on FDA and DEA policies regarding THC and CBD. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, suggesting it was part of a congressional document production, though no specific individuals (including Epstein) are named on this page.
HOUSE_OVERSIGHT_024710.jpg
This document is page 74 of a 'Cannabis Investment Report' published by Ackrell Capital in December 2017. It details the regulatory framework for drugs under the FD&C Act, defining what constitutes a drug and outlining the FDA's four-step approval process (from animal testing to New Drug Application). The document bears a 'HOUSE_OVERSIGHT_024710' Bates stamp, indicating it was part of a document production for a Congressional investigation.
HOUSE_OVERSIGHT_024707.jpg
This document is page 71 of a 2017 report by Ackrell Capital regarding the U.S. legal landscape for cannabis. It details the DOJ's 'Cole Memo' (2013) which outlined enforcement priorities for federal prosecutors regarding marijuana offenses. It also references U.S. Attorney General Jeff Sessions' comments during his 2017 confirmation hearings regarding these priorities and federal resource allocation. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, indicating it was part of a document production to Congress.
HOUSE_OVERSIGHT_024706.jpg
This document is page 70 of a December 2017 Cannabis Investment Report by Ackrell Capital, bearing a House Oversight Bates stamp. It details the legal landscape of THC under the Controlled Substances Act (CSA), outlining the history of DEA regulations, the 2004 Ninth Circuit court ruling regarding synthetic vs. natural THC, and federal penalties for violations including asset seizure. The report also discusses the DEA's 2016 policy shift intended to expand registered cannabis cultivators beyond the University of Mississippi's long-standing monopoly, noting that while applications were accepted, no new registrations had been issued at the time of the report.
HOUSE_OVERSIGHT_024705.jpg
This document is page 69 of a 2017 report by Ackrell Capital, LLC, titled 'Chapter IV U.S. Legal Landscape.' It provides a legal overview of the Controlled Substances Act (CSA), detailing the criteria for Schedule I-V drugs and specifically focusing on the classification and definition of marijuana as a Schedule I substance. The document bears a 'HOUSE_OVERSIGHT_024705' Bates stamp, suggesting it was included in evidence for a House Oversight Committee investigation, likely related to financial reviews.
HOUSE_OVERSIGHT_024704.jpg
This document is page 68 of a Cannabis Investment Report published by Ackrell Capital in December 2017. It features a diagram illustrating federal laws impacting the cannabis industry, categorized into Drug/Food Regulation, Banking/Finance, and Intellectual Property. The text specifically defines the Controlled Substances Act (CSA) of 1970 and notes its enforcement by the DEA. The document bears a 'HOUSE_OVERSIGHT' Bates stamp, suggesting it was part of a document production for a congressional investigation.
HOUSE_OVERSIGHT_024703.jpg
This document is page 67 of a 2017 report by Ackrell Capital titled 'Chapter IV U.S. Legal Landscape.' It analyzes the conflict between U.S. state and federal laws regarding the cannabis industry, detailing regulatory requirements, banking difficulties, and taxation issues. It mentions policy shifts by the DOJ, Treasury, DEA, and FDA up to October 2017. The document bears a 'HOUSE_OVERSIGHT' bates stamp, suggesting it was part of a document production for a congressional investigation, though the page itself contains no direct references to Jeffrey Epstein or his associates.
HOUSE_OVERSIGHT_024702.jpg
This page is an excerpt from an Ackrell Capital 'Cannabis Investment Report' dated December 2017. The text details the regulatory frameworks, licensing requirements, and taxation structures for recreational cannabis in various US states (WA, CA, MA, NV, OR, CO). While the document bears a 'HOUSE_OVERSIGHT' bates stamp, suggesting it was part of a document production for a congressional investigation (possibly involving financial records), the text on this specific page contains no mention of Jeffrey Epstein, his associates, or his specific financial transactions.
HOUSE_OVERSIGHT_024701.jpg
This document is page 65 (Chapter IV) of a 2017 report by Ackrell Capital regarding the U.S. legal landscape for cannabis. It details the history of CBD-specific legislation (Carly's Law, etc.) and the timeline of recreational legalization across various states between 2012 and 2016. While the document bears a 'HOUSE_OVERSIGHT' stamp, indicating it was part of a congressional investigation document production, the content is strictly an industry analysis of cannabis laws and contains no direct textual references to Jeffrey Epstein or his associates.
HOUSE_OVERSIGHT_024700.jpg
This document is page 64 of a 'Cannabis Investment Report' dated December 2017, authored by Ackrell Capital. It provides a detailed overview of Medical Cannabis Laws in the United States, discussing the history of legalization starting with California in 1996, the legal distinction between 'prescribing' and 'recommending' under the CSA, qualifying medical conditions (listing over 50), and state-specific restrictions such as Pennsylvania's 2016 law. The document contains a Bates stamp 'HOUSE_OVERSIGHT_024700', indicating it was part of a document production to the House Oversight Committee, likely within a larger tranche of financial or investment records.
HOUSE_OVERSIGHT_024699.jpg
This document is a page from an Ackrell Capital report (Chapter IV: U.S. Legal Landscape) featuring a map and list of U.S. state cannabis laws as of January 2018. It categorizes states by Recreational Law, Medical Cannabis Law, CBD/Limited Law, or No Law. While the document bears a 'HOUSE_OVERSIGHT' Bates stamp, suggesting it was part of a document production to Congress (potentially related to financial investigations involving Epstein or related banks), the content itself is purely market research regarding the cannabis industry and contains no specific mention of Jeffrey Epstein or his associates.
HOUSE_OVERSIGHT_024698.jpg
This page from a December 2017 Ackrell Capital report analyzes U.S. state laws regarding cannabis, categorizing them into medical, CBD/limited, and recreational frameworks. It notes that 47 out of 51 jurisdictions have enacted some form of cannabis law and discusses specific nuances in states like Florida, Delaware, and the District of Columbia.
HOUSE_OVERSIGHT_024697.jpg
This document is a page from a 2017 report by Ackrell Capital, LLC regarding the U.S. legal landscape for the cannabis industry. It discusses the conflict between federal prohibition and state legalization, noting that while federal policy restricts cannabis, 46 states permitted some use at the time. The document predicts a shift toward federal approval and legalization. It bears the stamp 'HOUSE_OVERSIGHT_024697', indicating it was part of a document production for a House Oversight Committee investigation, though the text itself contains no direct references to Jeffrey Epstein.
HOUSE_OVERSIGHT_024695.jpg
This document outlines the opportunities, challenges, and future outlook for digital media within the cannabis industry. It highlights the potential for premium content and mobile applications while noting the difficulties posed by limited advertising and restrictions from major platforms like Facebook and Google.
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein entity